Italian expert panel consensus statements on two-drug antiretroviral regimens to treat naive and virologically suppressed HIV-1 infected patients

被引：0

作者：

Antinori, Andrea ^{[1
]}

Santoro, Maria Mercedes ^{[2
]}

Gagliardini, Roberta ^{[1
]}

Marchetti, Giulia ^{[3
]}

Mondi, Annalisa ^{[1
]}

Cento, Valeria ^{[4
]}

Perno, Carlo Federico ^{[5
,22
]}

Andreoni, Massimo ^{[6
]}

Ceccherini-Silberstein, Francesca ^{[2
]}

Cossarizza, Andrea ^{[7
]}

Clerici, Mario ^{[8
,9
]}

Monforte, Antonella D'Arminio ^{[10
]}

De Luca, Andrea ^{[11
]}

Di Biagio, Antonio ^{[12
]}

Di Perri, Giovanni ^{[13
]}

Galli, Massimo ^{[14
]}

Girardi, E. ^{[1
]}

Gori, Andrea ^{[15
]}

Lazzarin, Adriano ^{[16
]}

Lichtner, Miriam ^{[17
]}

Lo Caputo, Sergio ^{[18
]}

Madeddu, Giordano ^{[19
]}

Maggiolo, Franco ^{[20
]}

Mussini, Cristina ^{[21
]}

Re, Maria Carla ^{[23
]}

Ripamonti, Diego ^{[24
]}

Rizzardini, Giuliano ^{[25
]}

Zazzi, Maurizio ^{[26
]}

机构：

[1] IRCCS, Natl Inst Infect Dis L Spallanzani, Rome, Italy

[2] Univ Roma Tor Vergata, Dept Expt Med, Rome, Italy

[3] Univ Milan, Clin Infect Dis, Dept Hlth Sci, ASST Santi Paolo & Carlo,Presidio San Paolo, Milan, Italy

[4] Univ Milan, Residency Microbiol & Virol, Milan, Italy

[5] Univ Milan, Dept Oncol & Oncohematol, Milan, Italy

[6] Univ Roma Tor Vergata, Infect Dis, Rome, Italy

[7] Univ Modena & Reggio Emilia, Dept Med & Surg Sci Children & Adults, Modena, Italy

[8] Univ Milan, Dept Pathophysiol & Transplantat, Milan, Italy

[9] IRCCS Don Carlo Gnocchi Fdn, Milan, Italy

[10] Univ Milan, Inst Infect Dis, Dept Hlth Sci, ASST Santi Paolo & Carlo, Milan, Italy

[11] Siena Univ Hosp, Infect Dis Unit, Siena, Italy

[12] Policlin Hosp San Martino, Infect Dis Clin, Genoa, Italy

[13] Univ Turin, Dept Med Sci, Unit Infect Dis, Turin, Italy

[14] Univ Milan, Infect Dis Unit, DIBIC Luigi Sacco, Milan, Italy

[15] Univ Milan, Fdn IRCCS Ca Granda, Infect Dis Unit, Osped Maggiore Policlin, Milan, Italy

[16] IRCCS San Raffaele Sci Inst, Clin Infect Dis, Milan, Italy

[17] Sapienza Univ, Dept Publ Hlth & Infect Dis, Rome, Italy

[18] Univ Bari Aldo Moro, Clin Infect Dis, Bari, Italy

[19] Univ Sassari, Dept Clin & Expt Med, Sassari, Italy

[20] AO Giovanni XXIII, Div Infect Dis, Bergamo, Italy

[21] Azienda Osped Univ Policlin Modena, Infect Dis Clin, Modena, Italy

[22] Univ Milan, Oncol & Oncolzematol, Milan, Italy

[23] Univ Bologna, Sch Med, Microbiol Sect, Dept Expt Diagnost & Specialty Med, Bologna, Italy

[24] ASST Papa Giovanni XXIII, Infect Dis Unit, Bergamo, Italy

[25] ASST Fatebenefratelli Sacco, Div Infect Dis, Milan, Italy

[26] Univ Siena, Dept Med Biotechnol, Siena, Italy

来源：

NEW MICROBIOLOGICA | 2019年 / 42卷 / 02期

关键词：

HIV; Two-drug regimens; Dolutegravir; Antireuoviral therapy; HIV drug-resistance; Virological efficacy; ATAZANAVIR/RITONAVIR PLUS LAMIVUDINE; HIV-INFECTED PATIENTS; REVERSE-TRANSCRIPTASE INHIBITOR; RITONAVIR-BOOSTED ATAZANAVIR; NON-INFERIORITY; OPEN-LABEL; TRIPLE THERAPY; DUAL THERAPY; TENOFOVIR-EMTRICITABINE; BUDGET IMPACT;

D O I：

暂无

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

New strategies for HIV treatment able to reduce drug-exposure, medium-long term toxicities and costs are a recognized clinical need. The availability of newer drugs with improved potency and tolerability, as well as high genetic barrier to resistance, makes antiretroviral-sparing strategies with two-drug regimens (2DRs) particularly attractive. Substantial evidence has been generated over the last few years supporting 2DR in virologically suppressed HIV infected patients for whom a therapy switch is planned. More recently, very promising data on 2DR in naive patients have also been reported. The main purpose of this consensus is to provide an overview of guideline indications and recommendations, and the most recent data from clinical studies of 2DR in both naive and virologically suppressed patients. As an expert consensus, suggestions and indications on the use and management of 2DR are also provided.

引用

页码：69 / 80

页数：12

共 102 条

[11] Resistance detected in PBMCs predicts virological rebound in HIV-1 suppressed patients switching treatment [J].

Armenia, Daniele ;

Zaccarelli, Mauro ;

Borghi, Vanni ;

Gennari, William ;

Di Carlo, Domenico ;

Giannetti, Alberto ;

Forbici, Federica ;

Bertoli, Ada ;

Gori, Caterina ;

Fabeni, Lavinia ;

Pinnetti, Carmela ;

Marocco, Raffaella ;

Latini, Alessandra ;

Ceccherini-Silberstein, Francesca ;

Mastroianni, Claudio Maria ;

Mussini, Cristina ;

Antinori, Andrea ;

Perno, Carlo Federico ;

Santoro, Maria Mercedes .

JOURNAL OF CLINICAL VIROLOGY, 2018, 104 :61-64

[12] Dual treatment with lopinavir-ritonavir plus lamivudine versus triple treatment with lopinavir-ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide reverse transcriptase inhibitor for maintenance of HIV-1 viral suppression (OLE): a randomised, open-label, non-inferiority trial [J].

Arribas, Jose R. ;

Girard, Pierre-Marie ;

Landman, Roland ;

Pich, Judit ;

Mallolas, Josep ;

Martinez-Rebollar, Maria ;

Zamora, Francisco X. ;

Estrada, Vicente ;

Crespo, Manuel ;

Podzamczer, Daniel ;

Portilla, Joaquin ;

Dronda, Fernando ;

Iribarren, Jose A. ;

Domingo, Pere ;

Pulido, Federico ;

Montero, Marta ;

Knobel, Hernando ;

Cabie, Andre ;

Weiss, Laurence ;

Gatell, Jose M. .

LANCET INFECTIOUS DISEASES, 2015, 15 (07) :785-792

[13]

Belmonti S., 2018, J ANTIMICROB CHEMOTH

[14] Bone mineral density and inflammatory and bone biomarkers after darunavir-ritonavir combined with either raltegravir or tenofovir-emtricitabine in antiretroviral-naive adults with HIV-1: a substudy of the NEAT001/ANRS143 randomised trial [J].

Bernardino, Jose I. ;

Mocroft, Amanda ;

Mallon, Patrick W. ;

Wallet, Cedrick ;

Gerstoft, Jan ;

Russell, Charlotte ;

Reiss, Peter ;

Katlama, Christine ;

De Wit, Stephane ;

Richert, Laura ;

Babiker, Abdel ;

Buno, Antonio ;

Castagna, Antonella ;

Girard, Pierre-Marie ;

Chene, Genevieve ;

Raffi, Francois ;

Arribas, Jose R. .

LANCET HIV, 2015, 2 (11) :E464-E473

[15]

Bertoldi A, 2017, NEW MICROBIOL, V40, P1

[16] Dolutegravir-based maintenance monotherapy versus dual therapy with lamivudine: a planned 24 week analysis of the DOLAM randomized clinical trial [J].

Blanco, Jose L. ;

Rojas, Jhon ;

Paredes, Roger ;

Negredo, Eugenia ;

Mallolas, Josep ;

Casadella, Maria ;

Clotet, Bonaventura ;

Gatell, Jose M. ;

de Lazzari, Elisa ;

Martinez, Esteban .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2018, 73 (07) :1965-1971

[17]

Cahn P., 2018, The Lancet

[18]

Cahn P., 2018, AIDS

[19] Dolutegravir-lamivudine as initial therapy in HIV-1 infected, ARV-naive patients, 48-week results of the PADDLE (Pilot Antiretroviral Design with Dolutegravir LamivudinE) study [J].

Cahn, Pedro ;

Rolon, Maria Jose ;

Figueroa, Maria Ines ;

Gun, Ana ;

Patterson, Patricia ;

Sued, Omar .

JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2017, 20

[20] Dual therapy with lopinavir and ritonavir plus lamivudine versus triple therapy with lopinavir and ritonavir plus two nucleoside reverse transcriptase inhibitors in antiretroviraltherapy-naive adults with HIV-1 infection: 48 week results of the randomised, open label, non-inferiority GARDEL trial [J].

Cahn, Pedro ;

Andrade-Villanueva, Jaime ;

Arribas, Jose R. ;

Gatell, Jose M. ;

Lama, Jiavier R. ;

Norton, Michael ;

Patterson, Patricia ;

Sierra Madero, Juan ;

Sued, Omar ;

Ines Figueroa, Maria ;

Jose Rolon, Maria .

LANCET INFECTIOUS DISEASES, 2014, 14 (07) :572-580

← 1 2 3 4 5 6 7 8 9 10 →